Lexeo Therapeutics

• Patients Clinical trials Expanded access Patient materials 345 Park Avenue South, 6th Floor New York, NY 10010 (212) 547-9879
• General Information info@lexeotx
• com (212) 547-9879
• LinkedIn Follow LEXEO on LinkedIn

Follow LEXEO on LinkedIn Gene therapy for diseases regardless of their prevalence LEXEO Therapeutics was founded in 2018, based on a well-established gene therapy research legacy at Weill Cornell Medicine’s Department of Genetic Medicine by a team of pioneering scientists, clinicians, and business leaders with deep expertise in gene therapy

LEXEO’s gene therapy product candidates target the underlying causes of both rare monogenic diseases and diseases affecting more prevalent patient populations We utilize adeno-associated viruses (AAV) that have been engineered to transfer therapeutic genes to patients LEXEO’s investigational therapies have the potential to address genetically defined cardiovascular and central nervous system (CNS) diseases that have eluded today’s existing drug delivery platforms